DNA-Based
RNA-Based
Live attenuated
Inactivated Virus
Protein subunit
Replicating viral vector
Non-replicating viral vector
Virus-like particle
Other Vaccines
Overview
HOW TO READ THE SYRINGE Graphic
Timeline
HOW Vaccines work
Stages of Development
Early Manufacturing
A Race ARound the World
list of vaccines by Category
Inactivated Virus
Live attenuated
Protein subunit
DNA-Based
RNA-Based
Replicating viral vector
Non-replicating viral vector
Virus-like particle
Other Vaccines
Vaccines in use
Data sourced from FasterCures, a center of the Milken Institute.
Interactive visualization by FirstPerson, a design & storytelling company.
Covid-19 Vaccine Tracker
Rapidly evolving, check back often.
Last updated:
August 18, 2022 10:40 AM
PST
276
vaccines are in development.
109
are now in clinical testing.
24
are in use.
See which vaccines are in use—and the newest updates.
The race to develop, approve, and manufacture COVID-19 vaccines is fluid—and urgent.
Scroll
Leading Vaccines
Phase
BioNTech/Pfizer
Approved
Moderna
Authorized
Oxford/AstraZeneca
Authorized
Janssen Pharma
Authorized
Sinovac/Instituto Butantan
Phase III
Wuhan Inst./Sinopharm
Phase III
Beijing Inst./Sinopharm
Phase III
Gamaleya Research Inst.
Phase III
CanSino Biologics
Phase III
Novavax
Phase III
vaccines in use
Key
Inactivated Virus
Live Attenuated Virus
Protein Subunit
DNA-Based
RNA-Based
Replicating Viral Vector
Non-Replicating Viral Vector
Virus-Like Particle
Other Vaccines
Vaccine Categories
Phases
I
Phase One
II
Phase Two
III
Phase Three
RR
Regulatory Review
AU
Authorized
View on desktop for the full experience.
View data for vaccines and treatments.
HOW TO READ THE
SYRINGE Graphic
There are currently
These fall into
At this time,
But not all vaccines are created equal.
276
vaccines in development for COVID-19.
This syringe represents vaccines currently in development. Each row is an individual vaccine.
How many are out of the pre-clinical phase?
9
different product categories/platforms.
Inactivated Virus
Live Attenuated Virus
Protein Subunit
DNA-Based
RNA-Based
Replicating Viral Vector
Non-Replicating Viral Vector
Virus-Like Particle
Other Vaccines
Vaccine Categories
More about the timeline, phases, manufacturing, and approaches to develop a COVID-19 vaccine.

Clinical trial phases read in columns from left to right on the syringe.
109
vaccines are in clinical testing.
I
II
III
RR
AU
Timeline
The vaccine development process typically takes a decade, but COVID-19 timelines are being compressed due to the global urgency of the pandemic.
Typical Vaccine Development
Possible COVID-19 vaccine development
12-18 MOnths
~10 Years
Many suggested a timeline from start of development to public use would be 12 -18 months from January 2020, when the genetic sequence of the virus that causes COVID-19 was published.

After completing large-scale clinical trials, the BioNTech/Pfizer vaccine was the first to be authorized for emergency use after 11 months.
How Vaccines Work
Weak Germs Injected
Vaccines contain the same germs that cause the disease, either killed or weakened, or they contain genetic instructions that code for the disease.
Antibodies Created
They stimulate your immune system to produce antibodies, as if you were exposed to the germ.
Immunity Developed
After getting vaccinated, one develops immunity to that disease without having to get it first.
Vaccines don’t cure diseases.
They prevent them.
stages of development
After pre-clinical studies are completed, the multiple phases of the clinical trial process test whether new vaccines are safe and effective before going public—culminating in a regulatory review. Phase IV is post-approval and monitors real-world effectiveness.
This process usually takes approximately 10 years, but governments and industry are fast-tracking these vaccines while maintaining safety and efficacy standards.
PRE
Pre-Clinical Phase
  • Collects data to support feasibility and safety
  • Involves iterative non-human testing
  • Evaluates toxic and pharmacological effects
  • Normally occurs before human testing can begin
I
Clinical phase
  • Small study of healthy people
  • Evaluates safety and immune response at different doses
  • Typically takes 1-2 years, but for COVID-19 trials, expected to take 3 months
II
Clinical phase
  • Studies 100s of people
  • Further evaluates safety, assesses efficacy, and informs optimal dose and vaccine schedule
  • Typically takes 2-3 years, but for COVID-19 trials, expected to take 8 months
III
Clinical phase
  • Studies 1000s of people
  • Further evaluates safety and efficacy
  • Typically takes 2-4 years, but for COVID-19 trials, may be combined with Phase II
RR
Regulatory Review
  • Government agency reviews trial data and licensing application information before authorization
  • Can happen while manufacturing has started
  • Typically takes 1-2 years, but for COVID-19, expedited to take a few months
IV
Clinical Phase
  • Post-approval studies that monitor effectiveness in real-world conditions
  • Testing begins after vaccine has been released to public
Once a vaccine is approved, do we get it right away?
Early Manufacturing
Oftentimes developers will try to ensure that enough of a vaccine is ready to ship the moment approval comes in by beginning the manufacturing process during clinical trials.
But a manufacturer loses significant resources if approval doesn’t come or a vaccine is no longer needed in the marketplace. The more vaccines produced, the more risk incurred. To mitigate risk and encourage manufacturing, governments, industry and international organizations are working together.
Pre
I
II
III
RR
IV
NON-IDEAL CASE
Developer manufactures mass quantities of a vaccine, but does not get approval, leaving the public without a vaccine and resources put into manufacturing lost. For COVID-19 vaccine development, private philanthropy has pledged to pay the lost costs for this scenario.
Pre
I
II
III
RR
IV
GOOD CASE
Developer gets fast approval, but has not manufactured enough of a vaccine to distribute in mass quantities. The public must wait longer for more vaccines to become available.
Pre
I
II
III
RR
IV
BEST CASE
Developer gets fast approval and has been concurrently manufacturing the vaccine during clinical trials.
The vaccine is now ready to distribute in mass quantities.
A race ARound the world
To expedite development and distribution of a vaccine, unprecedented international alliances have been formed and billions have been allocated. But simultaneous initial development will eventually give way, and only a select few of the most promising candidates will receive funding towards eventual licensing and distribution.
That is why many different types of vaccines are being researched and tested—some traditional, others experimental. Each product category has its own advantages and disadvantages, and we will likely need more than one vaccine to protect all people around the globe.
Meet the candidates.
DNA-Based
RNA-Based
Live attenuated
Inactivated Virus
Protein subunit
Replicating viral vector
Non-replicating viral vector
Virus-like particle
Other Vaccines
Inactivated Virus
Live attenuated
Protein subunit
DNA-Based
RNA-Based
Replicating viral vector
Non-replicating viral vector
Virus-like particle
Other Vaccines
Inactivated virus
These consist of viruses grown in culture and then killed as a means to reduce virulence (ability to infect and cause harm) and thus prevent infection from the vaccine. One benefit is they can be given to people with weakened immune systems. Examples include polio and influenza vaccines.
Bharat Biotech/ Indian Council of Medical Research/ National Institute of Virology/ Ocugen/ Precisa Medicamentos
Inactivated; whole-virion (COVAXIN) (BBV152)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
World Health Organization (WHO) granted Emergency Use Listing (EUL) on 11/3/2021; Phase III efficacy analysis results announced on 7/2/2021; Phase III second interim analysis results announced on 4/21/2021; Authorized for "emergency use" in Nepal and Zimbabwe as of March 2021; Phase II interim analysis and Phase I follow-up results published 3/8/2021; Phase III interim analysis results announced 3/3/2021; Neutralization of UK-variant with vaccine-elicited sera announced January 2021; India granted "permission for emergency use" on 01/03/2021; Phase I and II safety and immunogenicity data released December 2020 and published January 2021; Phase III began November 2020; Phase I/II study: Phase I began July 2020 and Phase II began September 2020, initial results expected September 2020; Animal study results released September 2020, Approved for intranasal booster dose trials February 2022
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
CTRI/2020/07/026300, NCT04471519, CTRI/2020/09/027674, CTRI/2020/11/028976, NCT04641481
Valneva/ Dynavax/ National Institute for Health Research, United Kingdom
Inactivated (Inactivated + CpG 1018), VLA2001
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for Japanese Encephalitis
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase III positive topline results announced 10/18/2021; Commenced recruitment of adolescents (12-17 years) into Phase III trial “Cov-Compare” and enrolled participants in the Phase I/II booster trial in September 2021; Initiated a further Phase III trial with participants aged 56 years and older in August 2021; Phase III began April 2021; Phase I/II data announced April 2021; Phase I/II began December 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04671017, NCT04864561
Sinovac/ Instituto Butantan/ Bio Farma
Inactivated (inactivated + alum); CoronaVac (formerly PiCoVacc); VACSERA in Egypt
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for SARS
Anticipated Next Steps
Anticipated Next Steps
n/a
The Egyptian Drug Authority (EDA) granted the Sinovac/VACSERA vaccine an emergency use license on 8/23/2021; Phase I/II clinical trials results in healthy children and adolescents aged 3-17 in China published 6/28/2021; World Health Organization (WHO) granted Emergency Use Listing (EUL) on 6/1/2021; Summary of clinical trial data released on 4/3/2021; Emergency use approval, or conditional marketing authorization, has been granted by over 30 countries as of 4/1/2021; Malaysia granted "conditional approval" on 3/2/2021; China's NMPA granted "conditional marketing authorization" on 2/8/2021; Phase III results (Brazil, Turkey, Indonesia, Chile) announced on 2/5/2021; Phase I/II safety, tolerability, and immunogenicity data in adults aged 60 years and older published on 2/3/2021; Sinovac filed for "conditional market authorization" with China’s National Medical Products Administration (NMPA) on 2/3/2021; Chile granted "emergency use" approval on 1/20/2021; Brazil granted "temporary authorization for emergency use" on 1/17/2021; Turkey granted "emergency use authorization" on 1/31/2021; Indonesia granted "emergency use approval" on 01/11/2021; Phase III efficacy results (Brazil) released early January 2021; Phase I/II complete analysis results published 11/17/2020; Phase III trial resumed in Brazil on 11/11/2020, Phase III trial suspended in Brazil on 11/09/2020; Received approval for Phase I/II trial in adolescents and children in September 2020; Phase III trial began end of July 2020; Phase II began June 2020, mid-phase II results released August 2020; Preliminary results from Phase I/II trials released June and September 2020 (aged 60+) 2020; Received early approval for "emergency use" in China (Aug 2020)
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04383574, NCT04352608, NCT04456595, NCT04551547, NCT04508075, NCT04582344, NCT04617483, NCT04651790, 669/UN6.KEP/EC/2020
Research Institute for Biological Safety Problems, Republic of Kazakhstan
Inactivated, (QazCovid-in®)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Kazakhstan lauched nationwide vaccine roll out as of 4/27/2021; Kazakhstan granted "temporary registration for nine months" as of 1/13/2021; Phase III began December 2020; Phase I/II began September 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04530357, NCT04691908
Beijing Institute of Biological Products/ Sinopharm
Inactivated, (BBIBP-CorV)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Vietnam granted approval on 6/4/2021; World Health Organization (WHO) granted Emergency Use Listing (EUL) on 5/7/2021; Indonesia granted "emergency use" approval on 4/30/2021; Hungary granted "emergency use" approval on 1/29/2021; Pakistan granted "emergency use authorization" on 1/18/2021; China "granted conditional market approval" on 12/31/2020; Midterm clinical results released on 12/30/2020; Bahrain National Health Regulatory Authority (NHRA) "approved" on 12/13/2020; UAE Ministry of Health and Prevention (MOHAP) announced "official registration" on 12/9/2020, following review of Phase III interim analysis; Phase I/II results published October 2020; Phase III trial began July 2020; Received early approval for "emergency use" in China (Aug 2020) and the UAE (Sep 2020)
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ChiCTR2000032459, ChiCTR2000034780, NCT04510207, NCT04560881
Shenzhen Kangtai Biological Products Co.,Ltd./ Beijing Minhai Biotechnology Co., Ltd.
Inactivated SARS-CoV-2 vaccine, Vero cell, (KCONVAC)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Indonesia granted "emergency use authorization" in November 2021; Phase III began June 2021; Received early approval for "emergency use" in China in May 2021; Phase I/II results announced April 2021; Phase I/II study began October 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ChiCTR2000038804, ChiCTR2000039462, NCT04758273, NCT04756323, NCT04852705
Erciyes University
Inactivated; (ERUCOV-VAC), (TURKOVAC)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase III began June 2021; Phase II dosed February 2021; Phase I began November 2020, completed on December 14, 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04691947, NCT04824391, NCT04942405
Wuhan Institute of Biological Products/ Sinopharm
Inactivated
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
China granted "conditional approval" on 2/25/2021; Applied for regulatory approval in China as of February 2021; Phase III trial began July 2020; Phase I/II early trial results released June 2020, Phase I/II interim analysis published August 2020; Received early approval for "emergency use" in China (Aug 2020) and the UAE (Sep 2020)
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ChiCTR2000031809, ChiCTR2000034780, ChiCTR2000039000, NCT04510207, NCT04612972
Kocak Farma Ilac ve Kimya San. A.S.
Inactivated
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase III began June 2021; Phase I began March 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04838080, NCT04942405, NCT05035238
Chumakov Federal Scientific Center for Research and Development of Immune and Biological Products of the Russian Academy of Sciences
Whole virion inactivated vaccine, CoviVac
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase III began March 2021; Russia "registered" the vaccine in February 2021; Clinical trials began Ocotober 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Institute of Medical Biology, Chinese Academy of Medical Sciences
Inactivated
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase III dosed (Malaysia) late January 2021; Phase II began June 2020; Phase I began May 2020, results released October 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04412538, NCT04470609, NCT04659239
Shifa Pharmed Industrial Co
COVID-19 inactivated vaccine (COVIran Barekat)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I study in children ages 12-18 began November 2021; Iran granted emergency use authorization on 6/14/2021; Phase II/III trial in adults 18-75 years of age began March 2021; Phase I trial in adults 51-75 years of age began March 2021; Phase I trial in adults 18-50 years of age began December 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
IRCT20201202049567N1, IRCT20201202049567N2, IRCT20201202049567N3
Government Pharmaceutical Organization (GPO; Thailand) / Dynavax / PATH
Inactivated, Newcastle Disease Virus (NDV) based chimeric vaccine with or without the adjuvant CpG 1018; (NDV-HXP-S)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II began March 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04764422
KM Biologics
Inactivated (inactivated + alum); (KD-414)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for JE, Zika
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II study began March 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
jRCT2071200106
Institute of Vaccines and Medical Biologicals (IVAC; Vietnam) / Dynavax / PATH
Egg-based, inactivated, whole chimeric Newcastle Disease Virus (NDV) expressing membrane-anchored pre-fusion-stabilized trimeric SARS-CoV-2 S protein (Hexapro) + CpG 1018, (COVIVAC)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II began March 2021, Phase I is expected to be completed by end of May 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04830800
Laboratorio Avi-Mex/ National Council of Science and Technology, Mexico/ Agencia Mexicana de Cooperación Internacional para el Desarrollo (AMEXID)
Recombinant Newcastle disease virus (rNDV), ("Patria")
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I began May 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04871737, NCT05205746
Scientific and Technological Research Council of Turkey (TUBITAK)
Adjuvanted inactivated vaccine
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I began end of April 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04866069
National Research Centre, Egypt
Inactivated; whole virus; (NRC-VACC-01)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Pre-clinical study results published March 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Institute Butantan (Brazil) / Dynavax / PATH
Egg-based, inactivated, whole chimeric Newcastle Disease Virus (NDV) expressing membrane-anchored pre-fusion-stabilized trimeric SARS-CoV-2 S protein (Hexapro) + CpG 1018
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Sinovac/ Dynavax
Inactivated + adjuvant (CpG 1018)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Selcuk University
Inactivated
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Osaka University / BIKEN / NIBIOHN
Inactivated
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Developer / Researcher

Product Description
PRE
I
II
III
RR
AU
Live attenuated virus
In contrast to inactivated virus vaccines, these vaccines, also whole viruses, are live to elicit a stronger immune response but weakened to reduce virulence. Examples include those for measles, mumps, and tuberculosis.
Codagenix / Serum Institute of India
Single-dose, intranasal, live attenuated vaccine, (COVI-VAC)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for HAV, InfA, ZIKV, FMD, SIV, RSV, DENV
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I topline safety and immunogenicity data and ongoing acceleration into Phase II/III trials announced September 2021; Pre-clinical research published June 2021; Phase I trial dosed January 2021, initial data expected by mid-2021; Phase I recruitment began December 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04619628, NCT05233826
Meissa Vaccines
Intranasal live-attenuated chimeric vaccine candidate, (MV-014-212)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for RSV
Anticipated Next Steps
Anticipated Next Steps
n/a
Preliminary clinical data on safety and immunogenicity released October 2021; Pre-clinical data released August 2021; Phase I enrollment began March 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04798001
Indian Immunologicals Ltd/ Griffith University
Codon deoptimized live attenuated virus
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Mehmet Ali Aydinlar University/ Acıbadem Labmed Health Services A.S.
Codon deoptimized live attenuated vaccines
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Developer / Researcher
Product Description
PRE
I
II
III
RR
AU
Protein subunit
Rather than introducing whole viruses to an immune system, a fragment of the virus is used to trigger an immune response and stimulate immunity. Examples include the subunit vaccines against Hepatitis B and shingles.
Sanofi Pasteur/ GSK
Protein subunit; S protein, baculovirus production; (Vidprevtyn)
Product Description
Funder
Funder
n/a
Biomedical Advanced Research and Development Authority (BARDA)/ US Department of Health and Human Services (HHS)/ US Department of Defense (DoD)
Related use
Related use
n/a
Same platform as vaccine candidates for Influenza, SARS-CoV (FDA approved vaccine)
Anticipated Next Steps
Anticipated Next Steps
n/a
EMA began rolling review on 7/20/2021; Phase III began end of May 2021; Phase II interim results released May 2021; Phase II with refined antigen formulation began February 2021; Phase I/II interim safety and immunogenicity results released January 2021; Phase IIb expected to begin February 2021; Phase I/II interim results announced December 2020; Phase I/II began September 2020; Selected for US Operation Warp Speed in April 2020 and awarded funding in July 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04537208, NCT04762680, PACTR202011523101903
Novavax/Emergent Biosolutions/ Praha Vaccines/ Biofabri/ Fujifilm Diosynth Biotechnologies/ FDB/ Serum Institute of India/ SK bioscience/ Takeda Pharmaceutical Company Limited/ AGC Biologics/ PolyPeptide Group/ Endo
Protein subunit; Full length recombinant SARs COV-2 glycoprotein nanoparticle vaccine adjuvanted with Matrix M; (NVX-CoV2373) (SARS-CoV-2 rS)
Product Description
Funder
Funder
n/a
Coalition for Epidemic Preparedness (CEPI)/ US Department of Defense/ Gates Foundation
Related use
Related use
n/a
Same platform as vaccine candidates for RSV, CCHF, HPV, VZV, EBOV
Anticipated Next Steps
Anticipated Next Steps
n/a
Indonesia and the Philippines granted emergency use authorization (EUA) as of November 2021; Announced rolling regulatory submission to the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) for authorization on 10/27/2021; Phase III (U.K. trial) final analysis results published 6/30/2021; Phase III efficacy data released 6/14/2021; Updated PREVENT-19 trial protocol released on 5/10/2021; Announced preclinical data from NanoFlu/NVX-CoV2373 combination vaccine study on 5/10/2021; Initiated a pediatric expansion (12-17 years of age) of its Phase III clinical trial on 5/3/2021; Announced participation in Phase II clinical trial called "Comparing COVID-19 Vaccine Schedule Combinations – Stage 2" (Com-COV2) on 4/14/2021; Announced the initiation of crossover arms in two ongoing clinical trials on 4/5/2021; Phase III (UK) and Phase IIb ( South Africa) final efficacy results released 3/11/2021; Phase I/II trial dosed in Japan on 2/26/2021; Phase III trial (PREVENT-19) completed enrollment in the US and Mexico on 2/22/2021; Announced the start of the rolling review process with several regulatory agencies worldwide on 2/4/2021, including the European Medicines Agency (EMA), U.S. Food and Drug Administration (FDA), U.K. Medicines and Healthcare products Regulatory Agency (MHRA), and Health Canada; Phase III (UK) and Phase IIb ( South Africa) interim results released 1/28/2021; Phase III trial (PREVENT-19) initiated in the US and Mexico in December 2020, trial protocol released on website; FDA granted Fast Track Designation on 11/9/2020; Phase III dosed in the UK in October 2020, trial protocol released on website, interim data expected to be released in Q1 2021; Phase IIb trial began Aug 2020; Selected for US Operation Warp Speed July 2020; Phase I/II began end of May 2020, interim data expected to be released on 10/30/2020; Animal study & preliminary Phase I results released Aug 2020, Phase I results published Sept 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
EudraCT 2020-004123-16, NCT04368988, NCT04533399, NCT04583995, NCT04611802
Anhui Zhifei Longcom Biopharmaceutical/ Institute of Microbiology, Chinese Academy of Sciences
Adjuvanted recombinant protein (RBD-Dimer); ( ZF2001)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for MERS
Anticipated Next Steps
Anticipated Next Steps
n/a
China and Uzbekistan granted "emergency use" approval in March 2021; Phase III began December 2020; Phase I and II safety and immunogenicity data released December 2020; Phase II began July 2020; Received approval to launch clinical trials in China in June 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04445194, NCT04466085, NCT04550351, NCT04646590
Center for Genetic Engineering and Biotechnology (CIGB), Havana
CIGB-66 (RBD + aluminum hydroxide)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Cuba began rolling out the vaccine in a mass campaign in May 2021; Phase III began March 2021; Phase II began February 2021, Phase I (ABDALA) trial began December 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
RPCEC00000346
Medigen Vaccine Biologics Corp/ NIAID/ Dynavax
MVC-COV1901 vaccine injection; S-2 P protein + CpG 1018
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Announced (10/26/2021) as one of two candidate vaccines to be included in the Solidarity Trial Vaccines with WHO and the Ministries of Health of Colombia, Mali, and the Philippines; Phase III began October 2021; Taiwan began vaccine rollout during the week of 8/23/2021; Phase III expected to complete the recruitment (1,000 participants) by Q3 2021; Taiwan granted EUA approval on 7/19/2021, clinical trials are ongoing; Phase II interim analysis results released 6/10/21; Phase II study in elderly adults (65 years and older) began May 2021; Booster trial with third dose began May 2021; Phase II second dose vaccination completed on 4/28/2021; Phase I interim analysis results announced 4/7/2021; Phase II dosed January 2021; Phase I dosed in early October 2020; Received conditional approval for clinical testing on Aug 31 and was given full approval on Sept 30; Pre-clinical data released August 2020 and published November 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04487210, NCT04695652, NCT04822025, NCT04951388
Razi Vaccine and Serum Research Institute
SARS-CoV-2 recombinant Spike protein vaccine (Razi Cov Pars)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Iran issued an emergency use license in November 2021; Phase III began September 2021; Phase II began April 2021; Phase I began February 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
IRCT20201214049709N1, IRCT20201214049709N2, IRCT20201214049709N3
Vaxine Pty Ltd/ Flinders University/ Oracle/ Medytox/ Sypharma/ Oxford Expression Technologies
Protein subunit; recombinant spike protein with Advax adjuvant (COVAX-19), (SpikoGen)
Product Description
Funder
Funder
n/a
Innovate UK/ Australian Government
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Iran issued an emergency use permit in October 2021; Phase III trial dosed August 2021; Phase II trial dosed June 2021; Phase II and III trials will be initiated in Iran in the coming weeks as of May 2021; Phase I trial dosed July 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04453852, NCT04944368, NCT05005559, IRCT20150303021315N23, IRCT20150303021315N24
Biological E Ltd/ Dynavax/ Baylor College of Medicine
Protein subunit; (BECOV2)
Product Description
Funder
Funder
n/a
Coalition for Epidemic Preparedness Innovations (CEPI)
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase III began September 2021; Phase III clinical trial received approval to start by CDSCO in April 2021; CEPI partnership announced December 2020; Phase I/II began November 2020, interim data expected Q1 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
CTRI/2020/11/029032, CTRI/2021/08/036074
Instituto Finlay de Vacunas
rRBD produced in CHO-cell chemically conjugate to tetanus toxoid; (FINLAY-FR-2) (SOBERANA 02); PastuCovac in Iran
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Cuba granted "emergency approval" on 8/20/2021; Iran began producing the vaccine (as PastuCovac) in August 2021; Phase III efficacy data announced 7/8/2021; Phase III preliminary data announced on 6/19/2021; Phase I/II pediatric study (ages 3-18 years) began June 2021; Cuba began rolling out the vaccine in a mass campaign in May 2021; Phase III began March 2021; Phase II began December 2020; Phase I began October 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
IFV/COR/06 (RPCEC00000340), IFV/COR/08 (RPCEC00000347), IFV/COR/09 (RPCEC00000354)
Nanogen Pharmaceutical Biotechnology
Recombinant SARS-CoV-2 spike protein, aluminum adjuvanted, (Nanocovax)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase III began June 2021; Phase II began February 2021; Phase I began December 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04683484, NCT04922788
Federal Budgetary Research Institution (FBRI) State Research Center of Virology and Biotechnology "VECTOR"
Peptide vaccine, EpiVacCorona
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II interim results published March 2021; Phase III trial began November 2020; "Registered" for use in Russia in October 2020; Phase I/II trial began end of July 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04527575, NCT04780035
Shionogi & Co., Ltd./ National Institute of Infectious Disease, Japan
Recombinant protein vaccine S-268019, baculovirus expression
Product Description
Funder
Funder
n/a
Japan Agency for Medical Research and Development
Related use
Related use
n/a
Same platform as vaccine candidates for Influenza
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase II/III began October 2021; New Phase I/II clinical trial began in Japan at the end of July 2021, using a new formulation with a modified adjuvant to achieve a higher neutralizing antibody titer; Phase I/II clinical trial began December 2020. Results of 1/2 trial released December 2021. Top line results for Phase 2/3 additional dose released March 2022.
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
jRCT2051200092
Clover Biopharmaceuticals Inc./ Dynavax
Protein subunit, native like trimeric subunit spike protein; (SCB-2019)
Product Description
Funder
Funder
n/a
Coalition for Epidemic Preparedness (CEPI)
Related use
Related use
n/a
Same platform as vaccine candidates for HIV, RSV, Influenza
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase II/III (SPECTRA) trial succesfully met primary and secondary efficacy endpoints as of September 2021; Phase II/III (SPECTRA) trial with Dynavax adjuvant dosed March 2021, fully enrolled as of July 2021; Clover and GSK discontinued their partnership as of February 2021; Phase I safety and immunogenicity data released December 2020 and published January 2021; Phase II/III trial with Dynavax adjuvant expected to begin during first half of 2021; Phase II/III trial with GSK adjuvant is not expected to move forward; Pre-clinical results released September 2020; CEPI partnership expanded in July and November 2020, Phase I trial began June 2020, preliminary results expected in the near future
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04405908, NCT04672395
Instituto Finlay de Vacunas
RBD + adjuvant booster dose that contains spike-protein fragments, (SOBERANA PLUS)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Cuba granted emergency use authorization for use in convalescent individuals (19 years of age and older) on 9/23/2021; Phase I/II study in convalescent pediatric individuals (2-18 years of age) began September 2021; Phase II study in convalescent individuals began April 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
IFV/COR/11 (RPCEC00000366), IFV/COR/15 (RPCEC00000391)
Vaxxinity, Inc. (formerly COVAXX and United Neuroscience)/ University of Nebraska Medical Center (UNMC)/ DASA/ United Biomedical Inc. Asia
S1-RBD-protein; Multitope Peptide-Based Vaccine (MVP); UB-612
Product Description
Funder
Funder
n/a
Ministry of Health and Welfare in Taiwan
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I study extended with one booster dose in July 2021; Phase II/III trials expected to begin in Brazil, India, and other countries in Q2 2021; Phase I interim data announced 2/8/2021; Phase II began (Taiwan) February 2021; Phase II clinical trials granted conditional approval by Taiwan's Ministry of Health and Welfare on 1/29/2021; Phase I began (Taiwan) September 2020; Large scale human efficacy clinical trials expected to be conducted in Brazil and the US
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04545749, NCT04683224, NCT04773067, NCT04967742
AdaptVac (PREVENT-nCoV consortium)
Protein subunit, capsid-like particle (CLP); (ABNCoV2)
Product Description
Funder
Funder
n/a
European Commission (Horizon 2020 Program)
Related use
Related use
n/a
Same platform as vaccine candidates for HPV
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II (COUGH-1) study began March 2021, initial results expected to be released in July 2021; Pre-clinical data published January 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
West China Hospital, Sichuan University
RBD (baculovirus production expressed in Sf9 cells)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase II began November 2020; Phase I began end of August 2020; Animal study data published July 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ChiCTR2000037518, ChiCTR2000039994, NCT04530656, NCT04640402, NCT04718467
Laboratorios Hipra, S.A.
Recombinant Protein RBD
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II began August 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT05007509
SK bioscience/ GSK/ Institute for Protein Design (IPD) at the University of Washington (UW)
SARS-CoV-2 recombinant protein nanoparticle vaccine, (GBP510)
Product Description
Funder
Funder
n/a
Gates Foundation/ Coalition for Epidemic Preparedness (CEPI)
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II final data announced November 2021; Phase I/II interim data announced August 2021; Phase III IND submitted to the Korean Ministry of Food and Drug Safety in June 2021; Phase I/II began February 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04742738, NCT04750343
University Medical Center Groningen/ Akston Biosciences Corporation/ LakePharma
SARS-CoV-2-RBD-Fc fusion protein; (AKS-452)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II dosed April 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04681092
VIDO-InterVac, University of Saskatchewan
Protein subunit, adjuvanted microsphere peptide, (COVAC-1 & COVAC-2)
Product Description
Funder
Funder
n/a
The Government of Saskatchewan and the Canadian Federal Government
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II dosed February 2021; Animal testing results expected in April 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04702178
Kentucky BioProcessing (British American Tobacco)
RBD-based, (KBP-COVID-19)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II began recruiting December 2020, results expected mid-2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04473690
National Vaccine and Serum Institute, China
Recombinant SARS-CoV-2 Vaccine (CHO Cell)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II began recruiting April 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04869592
Instituto Finlay de Vacunas
RBD + Adjuvant (FINLAY-FR-1) (SOBERANA 01)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I preliminary report released March 2021; Phase I/II began August 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
IFV/COR/04 (RPCEC00000332), IFV/COR/05 (RPCEC00000338)
Center for Genetic Engineering and Biotechnology (CIGB), Havana
CIGB-669 (RBD-AgnHB)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I of Phase I/II (MAMBISA) trial began December 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
RPCEC00000345
University Hospital Tuebingen
SARS-CoV-2 HLA-DR peptides, (CoVAC-1)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I began December 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04546841
OSE Immunotherapeutics/ Cenexi
T cell-based vaccine platform (CoVepiT)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
First positive results announced 11/30/21; Phase I began May 2021; Pre-clinical results released in August 2020. Positive results released December 2021.
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04885361
Baiya Phytopharm/ Chula Vaccine Research Center
Plant-based subunit (RBD-Fc + Adjuvant)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I began September 2021; Animal trial results announced September 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04953078
Emergex Vaccines Holdings/ Center for Primary Care and Public Health (Unisante)/ University of Lausanne, Switzerland/ University of Lausanne Hospitals
T-Cell Priming Peptide Vaccine Against Coronavirus COVID-19, (naNO-COVID)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I (Stage II of a 2-part adaptive trial) began recruiting in December 2021 and is expected to be dosed in January 2022
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT05113862
HK inno.N Corporation (formerly CJ HealthCare)
SARS-CoV-2 Vaccine, (IN-B009)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I began September 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT05113849
Yisheng Biopharma
PIKA-Adjuvanted Recombinant SARS-CoV-2 Spike (S) Protein Subunit Vaccine
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I clinical trial registered August 2021; Pre-clinical data published March 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ACTRN12621001009808
Adimmune Corporation
Baculovirus-insect cells expression system, spike (S) protein (tAdimrSC-2f)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II dose finding study has received approval to begin in Indonesia as of September 2021; Phase I began end of August 2020; Phase II expected to begin November 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04522089
Shanghai Zerun Biotechnology Co., Ltd/ Walvax Biotechnology Co., Ltd
Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell); (202-CoV )
Product Description
Funder
Funder
n/a
Coalition for Epidemic Prepardeness (CEPI)
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I began July 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04982068
Walter Reed Army Institute of Research (WRAIR) / U.S. Army Medical Research and Development Command
Protein subunit; S protein (SpFN)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I began recruiting April 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04784767
Guangdong Provincial Center for Disease Control and Prevention/ Gaozhou Center for Disease Control and Prevention
Recombinant SARS-Cov-2 coronavirus fusion protein vaccine, (V-01)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I began April 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ChiCTR2100045108, ChiCTR2100045107
University of Queensland/CSL/Seqirus
Protein subunit; molecular clamp stabilized Spike protein with MF59 adjuvant
Product Description
Funder
Funder
n/a
Coalition for Epidemic Preparedness (CEPI)/Queensland Government/Federal Government (Australia)/Paul Ramsay Foundation
Related use
Related use
n/a
Same platform as vaccine candidates for Nipah, influenza, Ebola, Lassa
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I trial began July 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ACTRN12620000674932p, ISRCTN51232965, NCT04495933
PT Bio Farma
SARS-CoV-2 Protein Subunit Recombinant Vaccine
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II expected to begin November 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT05067894
Sinocelltech Ltd.
Bivalent Recombinant Trimeric S Protein Vaccine against SARS-CoV-2 Variants, (SCTV01C)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II/III, multicenter, randomized, double-blinded trials (designed to evaluate the safety, tolerability, immunogenicity, and protective efficacy of SCTV01C in healthy population aged ≥18 years previously vaccinated with inactivated, adenovirus vectored, or mRNA COVID-19 vaccine) expected to begin late October 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT05043311, NCT05043285
Clover Biopharmaceuticals AUS Pty Ltd
Adjuvanted recombinant SARS-CoV-2 trimeric S-protein (from B.1.351 variant) subunit vaccine; (SCB-2020S)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase II expected to begin August 2021; Pre-clinical data announced May 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04950751
VaxForm
CoV2-OGEN1, protein-based vaccine
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I expected to begin June 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04893512
PDS Biotechnology
PDS-0203; Versamune T-cell activating technology
Product Description
Funder
Funder
n/a
The Ministry of Science, Technology and Innovation of Brazil (MCTI)
Related use
Related use
n/a
Same platform as vaccines against cancers, HBV, influenza, and tuberculosis
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II is expected to to begin by Q2/3 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Intravacc/Epivax
Outer Membrane Vesicle (OMV)-subunit
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Pre-clinical data announced April 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
IMV, Inc., Canadian Center for Vaccinology at Dalhousie University, Izaak Walton Killam Health Center, Nova Scotia Health Authority, Canadian Immunization Research Network, University of Laval, Global Urgent and Advanced Research and Development in Canada
Protein subunit; DPX-COVID-19, protein subunit, peptide antigens formulated in LNP
Product Description
Funder
Funder
n/a
National Research Council of Canada Industrial Research Assistance Program (NRC IRAP), Atlantic Canada Opportunities Agency (ACOA), and Next Generation Manufacturing Canada (NGen)
Related use
Related use
n/a
Same platform as vaccine candidates for cancer and infectious diseases, including malaria and anthrax
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II expected to begin by end of 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Flow Pharma
Protein subunit, peptide
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for Ebola, Marburg, HIV, Zika, Influenza, HPV therapeutic vaccine, Breast Cancer
Anticipated Next Steps
Anticipated Next Steps
n/a
Pre-clinical study results published May 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Generex / EpiVax
Protein subunit; Ii-Key peptide
Product Description
Funder
Funder
n/a
Beijing Youfeng Biological Technology, Ltd (Youfeng-BI)
Related use
Related use
n/a
Same platform as vaccine candidates for HIV, SARS-CoV, Influenza
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Vaxil Bio
Protein subunit; peptide
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Vaxil has put its COVID-19 vaccine work on temporary hold as of May 31, 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Bogazici University
Peptide + novel adjuvant
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Clinical trials expected to begin summer 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
LakePharma, Inc.
Protein subunit, nanoparticle vaccine
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Farmacológicos Veterinarios SAC (FARVET SAC) / Universidad Peruana Cayetano Heredia (UPCH)
RBD protein (baculovirus production) + FAR-Squalene adjuvant
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as multiple vaccine candidates
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
MOGAM Institute for Biomedical Research, GC Pharma
Protein subunit
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Axon Neuroscience SE
Peptides derived from Spike protein; (ACvac1)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Pre-clinical results released September 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Vabiotech
Protein subunit, recombinant S protein in IC-BEVS
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Neo7Logix
Peptides
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Ohio State University/ Kazakh National Agrarian University
RBD protein delivered in mannose-conjugated chitosan nanoparticle
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Tampere University
Recombinant S protein produced in BEVS
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Kazakh National Agrarian University, Kazakhstan/ National Scientific Center for Especially Dangerous Infections
Recombinant spike protein with Essai O/W 1849101 adjuvant
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Kazakh National Agrarian University
Recombinant spike protein with Essai O/W 1849101 adjuvant
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Max-Planck Institute of Colloids and Interfaces
Recombinant S protein
Product Description
Funder
Funder
n/a
KHAN-1 Technology Transfer Fund I GmbH & Co KG
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
AnyGo Technology
Protein subunit, recombinant S1-Fc fusion protein
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Izmir Biomedicine and Genome Center
Recombinant S protein
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
iBio / CC-Pharming
Protein subunit; Subunit protein, plant produced
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
BiOMVis Srl/ University of Trento
OMV-based vaccine
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Heat Biologics (Zolovax)/ University of Miami/ Waisman Biomanufacturing
Protein subunit (gp-96 backbone)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for cancer (NSCLC), HIV, malaria, Zika
Anticipated Next Steps
Anticipated Next Steps
n/a
Animal data released August 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
St. Petersburg Scientific Research Institute of Vaccines and Serums
Protein subunit, recombinant protein, nanoparticles (based on S-protein and other epitopes)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ImmunoPrecise/ LiteVax BV
Spike-based (epitope screening)
Product Description
Funder
Funder
n/a
TRANSVAC2
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Lomonosov Moscow State University
Structurally modified spherical particles of the tobacco mosaic virus (TMV)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
National Research Centre, Egypt
Protein Subunit S, N, M & S1 protein
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
EpiVax / University of Georgia
Protein subunit; S protein
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for Inf H7N9
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Research Institute for Biological Safety Problems, Rep of Kazakhstan
Protein subunit
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Baylor College of Medicine
Protein subunit; S1 or RBD protein
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for SARS
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
University of Alberta
Protein subunit; spike based
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for Hepatitis C
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Soligenix/ University of Hawaii at Mānoa
CiVax™ COVID-19 vaccine candidate; spike protein + novel adjuvant
Product Description
Funder
Funder
n/a
Soligenix, Inc.
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Pre-clinical testing results released in July 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Intravacc/Epivax
Outer Membrane Vesicle (OMV)-peptide
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Neovii/Tel Aviv University
RBD-based
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
University of California, San Diego
Protein subunit; plant virus nanotechnology formulated as injectable and microneedle patch
Product Description
Funder
Funder
n/a
National Science Foundation (Rapid Response Research [RAPID] grant)
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Osaka University / BIKEN / National Institutes of Biomedical Innovation, Japan
Protein subunit, VLP-recombinant protein + adjuvant
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
InnoMedica
Protein subunit, TaliCoVax19
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Helix Biogen Consult, Ogbomoso & Trinity Immonoefficient Laboratory, Ogbomoso, Oyo State, Nigeria
Subunit
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
University of Pittsburgh
PittCoVacc, Protein subunit, microneedle arrays S1 subunit
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for MERS
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I to start as early as June 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
OncoGen
Protein subunit, synthetic long peptide vaccine candidate for S and M proteins
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Innovax / Xiamen University / GSK
Protein subunit; COVID-19 XWG-03 truncated Spike proteins
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for HPV
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Applied Biotechnology Institute, Inc.
Orally delivered, heat stable subunit
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
MIGAL Galilee Research Institute
Protein subunit; oral E. coli-based protein expression system of S and N proteins
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
University of Virginia
S subunit intranasal liposomal formulation with GLA/3M052 adjs.
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
University of San Martin and CONICET, Argentina
Protein subunit
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Quadram Institute Biosciences
OMV-based vaccine
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for Flu A, plaque
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ExpreS2ion
Protein subunit, drosophila S2 insect cell expression system VLPs
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Federal Budgetary Research Institution (FBRI) State Research Center of Virology and Biotechnology "VECTOR"
Subunit vaccine
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for Ebola
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
UMN Pharma (Shionogi)
Protein subunit; recombinant protein vaccine, utilizing baculovirus expression vector system technology
Product Description
Funder
Funder
n/a
Japan Agency for Medical Research and Development
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I to start by end of 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
EpiVax
Protein subunit EPV-CoV-19
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Sorrento Therapeutics
Recombinant fusion protein of the SARS-CoV-2 spike protein S1 domain and human IgG Fc (T-VIVA-19)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Animal study results released July 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
AJ Vaccines
Protein subunit; S protein
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Mynvax
RBD-protein
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Verndari/ University of California, Davis
Spike protein; VaxiPatch microneedle array dermal patch
Product Description
Funder
Funder
n/a
Biomedical Advanced Research and Development Authority (BARDA) Division of Research, Innovation, and Ventures (DRIVe)
Related use
Related use
n/a
Same platform as vaccines against influenza
Anticipated Next Steps
Anticipated Next Steps
n/a
Preliminary pre-clinical results are expected in the second half of 2020, Phase I trial is expected to begin thereafter; Selected by BARDA DRIVe for support in August 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Chulalongkorn University/ GPO, Thailand
RBD protein fused with Fc of IgG + Adjuvant
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Developer / Researcher
Product Description
PRE
I
II
III
RR
AU

DNA-Based
These next-gen vaccines work through introducing viral genetic material (DNA) that cells use to make viral proteins that induce a range of immune response types. They can potentially be developed more quickly and easily than other vaccines, but no DNA vaccines have been approved for human use.
Zydus Cadila Healthcare Limited
DNA; (ZyCoV-D) plasmid vaccine
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
India granted "emergency use approval" for use in adults and children aged 12 years and above on 8/20/2021; Applied to the office of Drug Controller General of India (DCGI) for EUA on 7/1/2021; Phase III data expected to be announced May 2021; Phase III dosed January 2021; Pre-clinical results released January 2021; DCGI approved start of Phase III trial in January 2021; Phase I/II study: Phase I began July 2020 and Phase II began August 2020, initial results expected September 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
CTRI/2020/07/026352, CTRI/2021/01/030416
Inovio Pharmaceuticals/ Beijing Advaccine Biotechnology/ VGXI Inc./ Richter-Helm BioLogics/ Ology Bioservices/ International Vaccine Institute/ Seoul National University Hospital/ Thermo Fisher Scientific/ Kaneka Eurogentec
DNA; (INO-4800) plasmid vaccine with electroporation
Product Description
Funder
Funder
n/a
Coalition for Epidemic Preparedness (CEPI) / Gates Foundation / US Department of Defense
Related use
Related use
n/a
Same platform as multiple vaccine candidates
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase III segment of INNOVATE trial has received regulatory authorizations to proceed in Brazil, Colombia, India, Mexico, Philippines, Thailand, and the U.S. as of 11/09/21; Announced (10/26/2021) as one of two candidate vaccines to be included in the Solidarity Trial Vaccines with WHO and the Ministries of Health of Colombia, Mali, and the Philippines; Phase III efficacy trial receives authorization to proceed from Brazil's ANVISA on 8/26/2021; Phase II preliminary results released on 5/7/2021; ex-US Global Phase III trial planning announced 4/23/2021; Study results on the human immune responses against variants of concern announced 4/15/2021; Phase I data published December 2020; Phase II dosed December 2020, as part of its Phase II/III clinical trial (INNOVATE); FDA partial clinical hold for planned Phase II/III trial reported on 9/28/2020; Phase I/IIa trial began July 2020; Animal study results released July 2020; Joined US Operation Warp Speed in June 2020; Phase I began April 2020, interim data of ongoing study released June 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ChiCTR2000038152, ChiCTR2000040146, NCT04336410, NCT04447781, NCT04642638
Osaka University/ AnGes/ Takara Bio/ Cytiva/ Brickell Biotech
DNA; (AG0301 & AG0302) plasmid vaccine + adjuvant
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase II/III trial began December 2020; Pre-clinical study results released October 2020; Phase I/II trials began end of June (AG0301) and August (AG0302) 2020, results expected during Q1 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
jRCT2051200085, jRCT2051200088, NCT04463472, NCT04527081, NCT04655625
Vaccibody AS
Second generation DNA plasmid vaccine, T-cell; VB10.2210 (C2)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II began October 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT05069623
Vaccibody AS
Second-generation DNA plasmid vaccine, RBD; VB10.2129 (C1)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II began October 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT05069623
Genexine Consortium (GenNBio, International Vaccine Institute, Korea Advanced Institute of Science and Technology (KAIST), Pohang University of Science and Technology (POSTECH)/ Binex/ PT Kalbe Pharma
DNA; (formerly GX-19) (GX-19N)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase II/III study expected to begin in Indonesia as of July 2021; Phase IIa began February 2021; Updated development plan to GX-19N formula and will reconduct Phase I/IIa study as of December 2020. Phase I of Phase I/IIa study began end of June 2020; Animal study results announced August 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04445389, NCT04715997
GeneOne Life Science
DNA; (GLS-5310)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase IIa expected to be dosed July 2021; Phase I/IIa began December 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04673149
Entos Pharmaceuticals/ Cytiva
DNA; (Covigenix)
Product Description
Funder
Funder
n/a
Canadian Institutes of Health Research (CIHR)/ Research Nova Scotia (RNS)/ Institute for Ageing (IA)/ National Research Council of Canada Industrial Research Assistance Program (NRC IRAP)
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II began April 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04591184
Takis/ Applied DNA Sciences/ Evvivax/ Rottapharm Biotech
DNA (COVID-eVax)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II began March 2021, announced the authorization of the clinical trial by the Italian Medicines Agency (AIFA) on 2/3/2021; Pre-clinical results released in May and July 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
EudraCT 2020-003734-20, NCT04788459
Scancell/ University of Nottingham/ Nottingham Trent University
DNA; plasmid vaccine RBD&N;
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for cancer
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I COVIDITY clinical trial dosed October 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT05047445
BioNet Asia/ Technovalia/ Vax4COVID/ The University of Sydney/ The University of Western Australia/ Telethon Kids Institute/ PharmaJet
DNA; (COVIGEN) needle-free delivery
Product Description
Funder
Funder
n/a
Australian Government Medical Research Future Fund (MRFF)
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I dosed end of June 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04742842
Symvivo
DNA; bacTRL-Spike
Product Description
Funder
Funder
n/a
National Research Council of Canada Industrial Research Assistance Program (NRC IRAP)
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I dosed November 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04334980
OncoSec Medical Incorporated / Providence Cancer Institute
(CORVax12), IL-12 expression platform + “S” glycoprotein
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I dosed January 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04627675
The University of Hong Kong/ Immuno Cure 3 Limited
SARS-CoV-2 DNA Vaccine Delivered Intramuscularly Followed by Electroporation
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I expected to begin November 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT05102643
Statens Serum Institute, Denmark
DNA; (CoVAXIX) plasmid vaccine
Product Description
Funder
Funder
n/a
Folketing's Finance Committee
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I is expected to start in late 2020 or early 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
National Institute of Chemistry, Slovenia
Plasmid DNA, nanostructured RBD
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Globe Biotech Limited, Bangladesh
DNA plasmid vaccine
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
University of Cambridge/ DIOSynVax/ PharmaJet
DNA; (DIOS-CoVax2) synthetic gene inserts compatible with multiple delivery systems
Product Description
Funder
Funder
n/a
Innovate UK
Related use
Related use
n/a
Influenza, Ebola
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I expected to begin late fall 2020 or early 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Mediphage Bioceuticals/ University of Waterloo/ Lambton College
DNA; msDNA-VLP
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Immunomic Therapeutics/ EpiVax/ PharmaJet
DNA; plasmid vaccine, needle-free delivery
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for SARS
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Chula Vaccine Research Center
DNA with electroporation
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
OPENCORONA Project: Karolinska Institute/ Justus Liebig University Giessen/ Public Health Agency of Sweden (FoHM)/ IGEA/ Cobra Biologics/ Adlego Biomedical/ Region Stockholm
DNA with electroporation
Product Description
Funder
Funder
n/a
European Commission (Horizon 2020 Program)
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I expected to begin in 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
National Research Centre, Egypt
DNA; plasmid vaccine S, S1, S2, RBD & N
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Ege University Drug Development and Pharmacokinetic Research Application Center (ARGEFAR)/ Scientific and Technological Research Council of Turkey (TUBITAK)
DNA
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Developer / Researcher
Product Description
PRE
I
II
III
RR
AU
RNA-based
Similar to DNA vaccines, these experimental vaccines provide immunity through introduction of genetic material (RNA). RNA vaccines can also be potentially developed more quickly and easily than other vaccines. The BioNTech/Pfizer vaccine is the first RNA vaccine authorized for human use.
Moderna/ National Institute of Allergy and Infectious Diseases (NIAID)/ Biomedical Advanced Research and Development Authority (BARDA)/ Lonza/ Catalent/ Rovi/ Medidata/ BIOQUAL/ Baxter BioPharma Solutions/ Sanofi/ Recipharm
RNA; LNP-encapsulated mRNA (mRNA 1273), (TAK-919), (TAK-919), (SPIKEVAX™)
Product Description
Funder
Funder
n/a
Coalition for Epidemic Preparedness (CEPI)/ Biomedical Advanced Research and Development Authority (BARDA)
Related use
Related use
n/a
Same platform as vaccine candidates for multiple candidates
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase II/III KidCOVE study positive interim data announced 10/25/2021; Health Canada has approved the New Drug Submission (NDS-CV) for SPIKEVAX™ (elasomeran mRNA vaccine) in individuals 12 years of age and older as of 9/16/21; India granted "Emergency Use Authorization" on 6/29/2021; Clinical update on mRNA-1273's neutralizing activity against emerging variants announced 6/29/2021; Submitted authorization application to Swissmedic for use in adolescents on 6/14/2021; Filed for authorization with U.S. FDA for use in adolescents (12-18 years of age) on 6/10/2021; Filed for authorization with Health Canada for use in adolescents on 6/7/2021; Filed for conditional marketing approval (CMA) with the European Medicines Agency (EMA) for use in adolescents on 6/7/2021; Initiated rolling submission process with the U.S. FDA for a Biologics License Application (BLA) on 6/1/2021; Phase II/III study in adolescents met its primary immunogenicity endpoint as of 5/25/2021, data is expected to be submitted to regulators globally in early June 2021; Phase II initial booster data against variants announced 5/5/2021; World Health Organization (WHO) granted Emergency Use Listing (EUL) on 4/30/2021; Antibody persistence data published 4/6/2021; Phase II/III study (KidCOVE) dosed in pediatric population less than 12 years of age on 3/16/2021; Phase I study of next generation COVID-19 vaccine candidate, mRNA-1283, dosed on 3/15/2021; First participants dosed with modified COVID-19 vaccines, designed to address the potential need for booster vaccine candidates, in an amendment to the ongoing Phase II clinical study on 3/10/21; Provided strategy update for addressing SARS-CoV-2 variants of concern, including a variant-specific booster candidate (mRNA-1273.351) based on the B.1.351 variant first identified in the Republic of South Africa, on 2/24/2021; Results from an in vitro study on neutralization of variants of SARS-CoV-2 by mRNA-1273 vaccine-elicited sera announced January 2021; Phase I/II dosed in Japan (TAK-919) on 01/21/2021; Switzerland "authorized" on 01/12/2021; U.K. MHRA granted "temporary authorization" on 01/08/2021; European Commission granted a "conditional marketing authorization" on 01/06/2021; Israel granted "authorization to import" on 01/04/2021; Phase III interim safety and primary efficacy results published on 12/30/2020; Health Canada "authorized" on 12/23/2020; U.S. FDA issued "emergency use authorization" on 12/18/2020; Phase II/III study in adolescents ages 12 to less than 18 dosed on 12/10/2020; Submitted Emergency Use Authorization (EUA) request to the U.S. FDA on 11/30/2020; Phase III primary efficacy analysis results announced 11/30/2020; European Medicines Agency (EMA) started rolling review on 11/17/2020; Phase III interim analysis results announced 11/16/2020; Swissmedic started rolling review on 11/13/2020; UK Medicines and Healthcare products Regulatory Agency (MHRA) started rolling review on 10/27/2020; EMA confirmed marketing authorization submission eligibility on 10/14/2020; Health Canada rolling submission initiated on 10/13/2020; Study protocol for late-stage clinical trials released September 2020; Phase I interim data from older adult cohorts released Aug 2020 and published Sep 2020; Phase III COVE study began July 2020, completed enrollment on 10/22/2020; Animal study results published July/Aug 2020; Phase I interim results published July 2020; FDA fast track designation granted May 2020; Selected for US Operation Warp Speed in April 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04283461, NCT04405076, NCT04470427, NCT04649151, NCT04677660, NCT04712110, NCT04796896, NCT04847050
BioNTech/ Pfizer/ Fosun Pharma/ Rentschler Biopharma
3 LNP-mRNAs; BNT162
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase III topline results from a longer-term analysis in individuals 12 through 15 years of age announced 11/22/2021; U.S. FDA expanded the EUA of a booster dose to include individuals 18 years of age and older as of 11/19/2021; U.S. FDA Advisory Committee voted on 10/26/2021 to recommend the FDA grant Emergency Use Authorization (EUA) for the companies’ COVID-19 vaccine in children 5 to <12 years of age; Phase III topline results of the efficacy and safety of a 30-µg booster dose announced on 10/21/2021; Initial results from Phase II/III study (in participants 5 to 11 years of age) submitted to the U.S. FDA for the Agency’s initial review on 9/28/2021; U.S. FDA granted EUA for a booster dose in individuals 65 years of age and older, and individuals ages 18 through 64 within certain high-risk groups as of 9/22/2021; Phase II/III study (in participants 5 to 11 years of age) topline results announced 9/20/2021; U.S. FDA approved the Biologics License Application (BLA) for COMIRNATY® to prevent COVID-19 in individuals 16 years of age and older on 8/23/2021; U.S. FDA granted Priority Review designation for the Biologics License Application (BLA) on 7/16/2021 and the Prescription Drug User Fee Act (PDUFA) goal date for a decision by the FDA is in January 2022; Vietnam granted "emergency use" approval on 6/12/2021; European Union expanded Conditional Marketing Authorization (CMA) to include individuals 12-15 years of age on 5/28/2021; U.S. FDA expanded Emergency Use Authorization (EUA) to include individuals 12-15 years of age on 5/10/2021; Announced initiation of Biologics License Application (BLA) with the U.S. FDA on 5/7/2021; Phase III updated topline results announced 4/1/2021; Phase III trial in adolescents (12-15 years) topline results announced 3/31/2021; Phase I/II/III continuous study in children 11 years to 6 month old dosed March 2021; Real-world data gathered by the Israel Ministry of Health announced on 3/11/2021; Evaluation of the safety and immunogenicity of a third dose (30 µg booster of the current vaccine) 6 to 12 months after receiving initial two-dose regimen began 2/25/2021; New stability data at standard freezer temperature was submitted to the U.S. FDA as of 2/19/2021; Phase II/III study in healthy pregnant women 18 years of age and older dosed 2/18/2021; Results from in vitro studies on neutralization of variants of SARS-CoV-2 by BNT162b2 vaccine-elicited sera announced January 2021; Phase I (China) preliminary safety and immunogenicity data released January 2021; World Health Organization (WHO) granted Emergency Use Listing (EUL) on 12/31/2021; Argentina authorized under "emergency registration" on 12/22/2020; European Commission granted a "conditional marketing authorisation" (CMA) on 12/21/2020, following European Medicines Agency (EMA) recommendation to grant CMA; U.S. FDA issued "emergency use authorization" on 12/11/2020; Mexico COFEPRIS granted "emergency use authorization" on 12/11/2020; Saudi Food and Drug Authority (SFDA) "approved the registration" of the vaccine on 12/10/2020; Health Canada "authorized" on 12/9/2020; Bahrain granted "emergency use authorization" on 12/4/2020; U.K. MHRA granted "temporary authorization for emergency use" on 12/2/2020; Submitted Emergency Use Authorization (EUA) request to the U.S. FDA on 11/20/2020; Phase III complete analysis results announced 11/18/2020, interim analysis results announced 11/09/2020; Phase I data published October 2020; FDA approved late-stage trial enrollment of children 12 years and older in October 2020; EMA rolling submission initiated on 10/6/2020; Study protocol for late-stage clinical trials released Sept 2020; Amended protocol to FDA to expand trial enrollment to 44,000 participants; Phase IIb/III trial began Jul 2020; FDA granted Fast Track designation for BNT162b1 and BNT162b2 in Jul 2020; Selected for US Operation Warp Speed in Jul 2020; Phase I/II began Apr 2020; preliminary data released Jul 2020, additional data published Aug, Sept, and Dec 2020; Pre-clinical data released Sept 2020 and Dec 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ChiCTR2000034825, EudraCT 2020-001038-36, EudraCT 2020-003267-26, NCT04368728, NCT04380701, NCT04523571, NCT04537949, NCT04588480, NCT04649021, NCT04713553, NCT04754594
CureVac/Bayer/Novartis
RNA; mRNA (CVnCoV)
Product Description
Funder
Funder
n/a
Coalition for Epidemic Preparedness (CEPI); European Commission; Gates Foundation; Defense Advanced Research Projects Agency (DARPA); German Government; European Investment Bank (EIB); German Federal Ministry of Education and Research (BMBF)
Related use
Related use
n/a
Same platform as vaccine candidates for RABV, LASV, YFV, MERS, InfA, ZIKV, DengV, NIPV
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase IIb/III final analysis results released 6/30/2021; Phase IIb/III second interim analysis results released 6/16/2021; Initiated rolling submission with Swissmedic on 4/19/2021; Initiated rolling submission with European Medicines Agency (EMA) on 2/12/2021; Phase III trial began December 2020; Phase IIb/III (HERALD) trial began recruiting December 2020; Phase IIa trial began end of September 2020; Phase I trial began June 2020, interim results reported November 2020; Pre-clinical data released October 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
EudraCT 2020-004066-19, NCT04449276, NCT04515147, NCT04652102, NCT04674189, PER-054-20
ModernaTX, Inc.
RNA; LNP-encapsulated mRNA (mRNA 1273.211)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase II/III began May 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04927065
Arcturus/Duke-NUS/ Catalent
RNA; mRNA; (LUNAR-COV19), (ARCT-021)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for multiple candidates
Anticipated Next Steps
Anticipated Next Steps
n/a
Emergency Use Authorization filing in Vietnam could be as soon as December 2021; Phase IIIb (20,000 participants) dosing planned for first week of October 2021; Phase IIIa (600 participants) on track to initiate by end of September 2021; Phase IIa of Phase I/II trial began recruiting January 2021; Received approval to proceed with Phase II study in Singapore (December 2020) and the US (January 2021); Phase I/II interim data released December 2020; Pre-clinical results released September and December 2020; Phase I/II began August 2020, initial results expected Q4 2020; Received approval to launch clinical trials in Singapore end of July 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04480957, NCT04668339, NCT04728347, NCT05037097
People's Liberation Army (PLA) Academy of Military Sciences/ Walvax Biotech
mRNA (ARCoV)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase III expected to begin late May 2021; Phase II began January 2021; Phase Ib began end of October 2020; Pre-clinical results published September 2020; Phase I trial began end of June 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ChiCTR2000034112, ChiCTR2000039212, ChiCTR2100041855, NCT04847102
Gennova/ HDT Biotech Corporation
Self-amplifying mRNA vaccine; (HGCO19)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Mid-stage trials expected to begin September 2021; Phase I/II began April 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
CTRI/2021/04/032688
Daiichi-Sankyo/ University of Tokyo's Institute of Medical Science
RNA; mRNA (DS-5670)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase II segment of I/II clinical trial began November 2021; Phase I segment of I/II clinical trial began March 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Chulalongkorn University/ Chula Vaccine Research Center/University of Pennsylvania
LNP-mRNA; (ChulaCov19)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase II began August 2021; Phase I began June 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04566276
Elixirgen Therapeutics/ Fujita Health University
srRNA (EXG-5003)
Product Description
Funder
Funder
n/a
Japan Agency for Medical Research and Development (AMED)
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Entered into an exclusive licensing agreement with a global pharmaceutical company (currently undisclosed) in October 2021; Phase I/II began at Fujita Health University Hospital in May 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04863131
Sanofi Pasteur/ Translate Bio
LNP-mRNA
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II began March 2021, interim results expected in 3Q 2021; Pre-clinical results released October 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Imperial College London/ VacEquity Global Health
RNA; LNP-nCoVsaRNA
Product Description
Funder
Funder
n/a
UK Government
Related use
Related use
n/a
Same platform as vaccine candidates for EBOV, LASV, MARV, Inf (H7N9), RABV
Anticipated Next Steps
Anticipated Next Steps
n/a
Pre-clinical results published July 2020; Phase I/II trial began June 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ISRCTN17072692
Moderna/National Institute of Allergy and Infectious Diseases (NIAID)
RNA; LNP-encapsulated mRNA (mRNA 1273.351)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Initial booster data announced May 2021; Phase I began March 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04785144, NCT04405076
Providence Therapeutics Holdings Inc.
PTX-COVID19-B vaccine
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase II expected to begin June 2021; Pre-clinical results released May 2021; Phase I interim data announced May 2021; Phase I dosed January 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04765436
ModernaTX, Inc.
RNA; LNP-encapsulated mRNA (mRNA 1283)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I study of next generation COVID-19 vaccine candidate, mRNA-1283, dosed March 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04813796
ModernaTX, Inc.
RNA; LNP-encapsulated (mRNA-1273.529)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Rapidly advancing an Omicron-specific booster candidate (mRNA-1273.529) as of 11/26/2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
GlaxoSmithKline/CureVac
Next-generation multi-valent mRNA-based vaccine; (CV2CoV)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Pre-clinical data published 11/18/2021; Pre-clinical data released 5/13/2021; CureVac and GSK aim to develop a multi-valent candidate vaccine to address emerging variants for pandemic and endemic use; Development to begin immediately (February 2021) targeting vaccine availability in 2022, subject to regulatory approval
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
BiOCAD
RNA; liposome-encapsulated mRNA
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for cancer
Anticipated Next Steps
Anticipated Next Steps
n/a
Animal studies began April 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Monash Institute of Pharmaceutical Sciences (MIPS)/ Peter Doherty Institute for Infection and Immunity (Doherty Institute)
mRNA second generation COVID-19 vaccine
Product Description
Funder
Funder
n/a
mRNA Victoria, the agency of the Australian State of Victoria Government
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I expected to begin October 2021; Preliminary trial results are expected in the first half of 2022
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
SENAI CIMATEC/ HDT Bio Corp
Lipid-Inorganic Nanoparticle (LION™) formulated replicating RNA-based vaccine, (HDT-301)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I expected to begin July 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04844268
Globe Biotech Limited, Bangladesh
D614G variant LNP-encapsulated mRNA; (BANCOVID), (BANGAVAX)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Pre-clinical study published June 2021; Phase I/II protocol submitted to Bangladesh Medical Research Council (BMRC) on 1/17/2021 for approval to begin clinical trials; Pre-clinical data released September 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
CureVac/UK Government (Vaccines Taskforce)
Multiple mRNA vaccine candidates against SARS-CoV-2 variants
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Collaboration to develop and manufacture variant vaccines for commercial supply and distribution in the UK and its territories was entered in February 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
GeneOne Life Science / Houston Methodist
mRNA; (GLS-3000)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Infectious Disease Research Institute/ Amyris, Inc.
saRNA formulated in a NLC
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I expected to begin mid-2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Max-Planck Institute of Colloids and Interfaces
LNP-encapsulated mRNA encoding S
Product Description
Funder
Funder
n/a
KHAN-1 Technology Transfer Fund I GmbH & Co KG
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Chimeron Bio/ George Mason University's National Center for Biodefense and Infectious Disease
Self amplifying RNA, self-assembling delivery system
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Centro Nacional Biotecnologia (CNB-CSIC), Spain
RNA; Replicating defective SARS-CoV-2 derived RNAs
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
RNAimmune, Inc.
RNA; several mRNA candidates
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Greenlight Biosciences
mRNA
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Fudan University / Shanghai JiaoTong University / RNACure Biopharma
RNA; LNP-encapsulated mRNA cocktail encoding RBD
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Ziphius Therapeutics/ Ghent University
RNA; ZIP-1642, vaccine consists of a combination of mRNA molecules, encoding multiple SARS-CoV-2 antigens
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
CanSino Biologics/Precision Nanosystems
RNA; mRNA lipid nanoparticle (mRNA-LNP)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
China CDC / Tongji University / Stermina
RNA; mRNA
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
IDIBAPS- Hospital Clinic, Spain
mRNA
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Federal Budgetary Research Institution (FBRI) State Research Center of Virology and Biotechnology "VECTOR"
RNA; mRNA
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Fudan University / Shanghai JiaoTong University / RNACure Biopharma
RNA; LNP-encapsulated mRNA cocktail encoding VLP
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
eTheRNA Immunotherapies / EpiVax/ Nexelis/ REPROCELL / Centre for the Evaluation of Vaccination of the University of Antwerp
RNA; mRNA in an intranasal delivery system (cross-strain protective COV-2 mRNA) vaccine for high-risk populations
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Start Phase I early 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Selcuk University
mRNA
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Developer / Researcher
Product Description
PRE
I
II
III
RR
AU
Replicating viral vector
This involves putting a gene for a viral protein into a different virus (one that will not cause illness but can replicate). Replication of the viral vector also produces copies of the viral protein, which triggers an immune response to that protein. Examples include ebola and dengue vaccines.
Aivita Biomedical, Inc./ National Institute of Health Research and Development, Ministry of Health Republic of Indonesia
Dendritic cell vaccine AV-COVID-19
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase II began February 2021; Phase I began December 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04690387, NCT04685603, NCT04386252, NCT05007496
Mahidol University/ The Government Pharmaceutical Organization (GPO)/ Icahn School of Medicine at Mount Sinai
NDV-HXP-S vaccine, with or without the adjuvant CpG 1018
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II began March 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04764422
Israel Institute for Biological Research/ Weizmann Institute of Science
rVSV-SARS-CoV-2-S vaccine; (BriLife)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase IIb/III expected to begin September 2021; Phase III expected to begin October 2021; Phase I began November 2020 and Phase II began December 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04608305, NCT04990466
Cellid Co., Ltd./IAVI
AdCLD-CoV19
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I study of a revised version of the virus vector vaccine began September 2021; Phase IIa is expected to be dosed in early April 2021; Phase I/IIa trial began December 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04666012, NCT05047692
The University of Hong Kong/ Xiamen University/ Wantai Biological Pharmacy
Replicating viral vector, intranasal flu-based RBD (DelNS1-2019-nCoV-RBD-OPT1)
Product Description
Funder
Funder
n/a
Coalition for Epidemic Preparedness (CEPI)
Related use
Related use
n/a
Same platform as vaccine candidates for MERS
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I expected to begin in Hong Kong in April 2021; Phase I/II began in China during Fall 2020; Approved for clinical trials in September 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ChiCTR2000037782, ChiCTR2000039715, NCT04809389
Institut Pasteur/ Themis/ University of Pittsburgh CVR/ Merck Sharp & Dohme
Replicating viral vector; measles vector (V591); formerly (TMV-083)
Product Description
Funder
Funder
n/a
Coalition for Epidemic Preparedness (CEPI)
Related use
Related use
n/a
Same platform as vaccine candidates for West nile, CHIKV, Ebola, Lassa, Zika, MERS
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II began September 2020; Animal testing began April 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04497298, NCT04498247
Shenzhen Geno-Immune Medical Institute
Covid-19/aAPC vaccine
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I reportedly began February 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04299724
Tonix Pharma / Southern Research
Replicating viral vector; horsepox vector expressing S protein; (TNX-1800)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for smallpox, monkeypox
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I expected to begin during second half of 2021; Preliminary pre-clinical results reported on 3/17/2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Farmacológicos Veterinarios SAC (FARVET SAC)
Intranasal Newcastle disease virus vector (rNDV-FARVET) expressing S1 protein
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as multiple vaccine candidates
Anticipated Next Steps
Anticipated Next Steps
n/a
Pre-clinical results released March 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Farmacológicos Veterinarios SAC (FARVET SAC)
Intranasal Newcastle disease virus vector (rNDV-FARVET) expressing RBD protein
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as multiple vaccine candidates
Anticipated Next Steps
Anticipated Next Steps
n/a
Pre-clinical results released March 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
BiOCAD/ IEM
Replicating viral vector, live viral vectored vaccine based on attenuated influenza virus backbone (intranasal)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
University of Manitoba
Replicating VSV vector-based DC-targeting
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
IAVI/ Merck
Replicating viral vector, replication-competent VSV chimeric virus technology (VSVdeltaG) delivering the SARS-CoV-2 Spike (S) glycoprotein; (V590)
Product Description
Funder
Funder
n/a
Biomedical Advanced Research and Development Authority (BARDA); Defense Threat Reduction Agency (DTRA) of the U.S. Department of Defense (DoD)
Related use
Related use
n/a
Same platform as vaccine candidates for Ebola, Marburg, Lassa (including FDA-licensed Ebola vaccine, ERVEBO®)
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I expected to begin in late October 2020; Selected for US Operation Warp Speed in April 2020; clinical studies to start in 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04569786
Federal Budgetary Research Institution (FBRI) State Research Center of Virology and Biotechnology "VECTOR"
Replicating viral vector; measles vector
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Fundacao Oswaldo Cruz and Instituto Buntantan
Attenuated Influenza expressing an antigenic portion of the Spike protein
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Federal Budgetary Research Institution (FBRI) State Research Center of Virology and Biotechnology "VECTOR"
Replicating viral vector; VSV vector
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
The Lancaster University, UK
Avian paramyxovirus vector (APMV)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
DZIF - German Center for Infection Research/ CanVirex AG
Measles virus (S, N targets)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for Zika, H7N9, CHIKV
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
University of Western Ontario
Replicating viral vector; VSV-S
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for HIV, MERS
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Aurobindo
VSV-S
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Zydus Cadila Healthcare Limited
Replicating viral vector; measles vector
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
University of Wisconsin-Madison / FluGen/ Bharat Biotech
M2-deficient single replication (M2SR) influenza vector
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for influenza
Anticipated Next Steps
Anticipated Next Steps
n/a
Start Phase I trial in fall 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
KU Leuven
Replicating viral vector; YF17D Vector
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Federal Budgetary Research Institution (FBRI) State Research Center of Virology and Biotechnology "VECTOR"
Replicating viral vector, recombinant vaccine based on Influenza A virus, for the prevention of COVID-19 (intranasal)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for influenza
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Intravacc/ Wageningen Bioveterinary Research/Utrecht Univ.
Newcastle disease virus vector (NDV-SARS-CoV-2/Spike)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Developer / Researcher
Product Description
PRE
I
II
III
RR
AU
Non-replicating viral vector
This approach is similar to replicating viral vector vaccines in that a viral gene is added to a different, non-replicating, virus and delivered to the vaccine recipient.
University of Oxford, Oxford Biomedica, Vaccines Manufacturing and Innovation Centre, Pall Life Sciences, Cobra Biologics, HalixBV, Advent s.r.l., Merck KGaA, the Serum Institute, Vaccitech, Catalent, CSL, and AstraZeneca/IQVIA
Non replicating viral vector; COVID-19 Vaccine AstraZeneca in the U.K. (formerly AZD1222 and ChAdOx1), Covishield in India, (Vaxzevria)
Product Description
Funder
Funder
n/a
Coalition for Epidemic Preparedness Innovations (CEPI)/ UK Government/ Biomedical Advanced Research and Development Authority (BARDA)/ Gavi, the Vaccine Alliance
Related use
Related use
n/a
Same platform as vaccine candidates for influenza, TB, Chikungunya, Zika, MenB, plague
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase III safety and efficacy data published September 2021; Tolerability and immunogenicity results after a late second dose or a third dose released on 6/28/2021; Real-world data on vaccine effectiveness against hospitalizations due to the Delta variant released 6/14/2021; Japan granted authorization for "emergency use" on 5/21/2021; EMA updated guidance on very rare side effects announced 4/7/2021; Phase II dosing paused in children between the ages of 6 and 17 years pending MHRA review as of 4/6/2021; Phase III primary analysis (U.S. trial) results announced 3/25/2021; Phase III interim analysis (U.S. trial) results announced 3/22/2021; World Health Organization (WHO) granted Emergency Use Listing (EUL) on 2/15/2021; Phase II study in children between the ages of 6 and 17 years expected to begin in February 2021; Phase III (U.K., Brazil) and Phase I/II (U.K., South Africa) analyses data released on 2/3/2021; European Union (EU) granted "conditional marketing authorisation" on 1/29/2021; Brazil granted "temporary authorization for emergency use" on 1/17/2021; Pakistan granted "emergency use authorization" on 1/15/2021; India granted "emergency use authorisation" as well as Dominican Republic, El Salvador, Mexico and Morocco as of 1/6/2021; Argentina authorized under "emergency registration" on 12/30/2020; U.K. "authorised for emergency supply" on 12/30/2020; Phase I/II data (w/ booster dose) published on 12/17/2020; Phase III trials interim analysis results published 12/8/2020; Phase II/III (COV002) and Phase III (COV003) trial pooled interim analysis results released on 11/23/2020; Phase II/III trial interim results released Nov 2020; Study protocol for late-stage clinical trials released September 2020; AstraZeneca clinical trials resumed globally (in the UK on 9/14/2020, Brazil and South Africa on 9/15/2020, Japan on 10/2/2020, and the US on 10/23/2020); AstraZeneca voluntarily paused vaccination to allow independent review of safety data on 9/8/2020; Phase III trial began Jun 2020 and expanded into US in Aug 2020; Phase II/III began May 2020; Phase I/II trial interim results released Jul 2020; Selected for US Operation Warp Speed in May 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
CTRI/2020/08/027170, EudraCT 2020-001072-15, EudraCT 2020-001228-32, ISRCTN15638344, ISRCTN89951424, NCT04324606, NCT04400838, NCT04444674, NCT04516746, NCT04540393, NCT04568031, NCT04686773, PACTR202005681895696, PACTR202006922165132
Janssen Pharmaceutical Companies/ Beth Israel Deaconess Medical Center/ Emergent BioSolutions/ Catalent/ Biological E/ Grand River Aseptic Manufacturing (GRAM)/ Sanofi/ Merck
Ad26.COV2-S (or JNJ-78436725), Non replicating viral vector; Ad26 (alone or with MVA boost)
Product Description
Funder
Funder
n/a
Biomedical Advanced Research and Development Authority (BARDA)
Related use
Related use
n/a
Same platform as vaccine candidates for Ebola, HIV, RSV
Anticipated Next Steps
Anticipated Next Steps
n/a
Health Canada fully "approved" the vaccine in individuals 18 years of age and older on 11/24/2021; Phase I/IIa sub-study results published 7/14/2021; Johnson & Johnson statement on COVID-19 vaccine released 7/12/2021; Data on neutralizing activity against emerging variants announced 7/1/2021; U.K. MHRA granted "conditional marketing authorization" on 5/28/2021; CDC and FDA lift recommended pause on vaccine use in U.S. on 4/23/2021; Phase III ENSEMBLE primary data published on 4/21/2021; CDC and FDA recommended a pause on vaccine use in the U.S. as of 4/13/2021; Phase IIa trial expanded to include adolescents 12-17 years of age as of 4/2/2021; WHO issued "emergency use listing" on 3/12/2021; Granted Conditional Marketing Authorization by European Commission on 3/11/2021; Granted "Interim Order (IO) authorization" for emergency use by Health Canada on 3/5/2021; U.S. CDC's Advisory Committee on Immunization Practices (ACIP) has recommended the first single-shot COVID-19 vaccine for individuals 18 years of age and older on 2/28/2021; U.S. FDA issued "emergency use authorization" on 2/27/2021; Submitted "emergency use listing" to the World Health Organization (WHO) on 2/19/2021; Submitted "conditional marketing authorisation application" to the European Medicines Agency (EMA) on 2/16/2021; Janssen submitted application for "emergency use authorization" to the U.S. FDA on 2/4/2021; Phase III interim analysis results announced 1/29/2021; Phase I/IIa interim results published 1/13/2021; Phase III trial to study the safety and efficacy of a two-dose regimen began 11/15/2020 (ENSEMBLE 2); Phase III trial (ENSEMBLE) resumed recruitment on 10/23/2020, fully enrolled with ~45,000 participants as of 12/17/2020, interim data expected by the end of January 2021; Janssen Pharmaceutical Companies of Johnson & Johnson voluntarily paused dosing to allow independent review of safety data on 10/12/2020; Phase III trial (ENSEMBLE) began and study protocol released September 2020; Phase I/IIa began end of July 2020, interim results released September 2020; Animal study results published July and September 2020; Selected for US Operation Warp Speed in February 2020 and awarded funding in August 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
EudraCT 2020-002584-63, ISRCTN14722499, NCT04436276, NCT04505722, NCT04509947, NCT04535453, NCT04614948, NCT04765384
Gamaleya Research Institute
Adeno-based; (Gam-COVID-Vac) (Sputnik V)
Product Description
Funder
Funder
n/a
Russian Direct Investment Fund (RDIF)
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Final results of trials are expected to be ready by October 2021; Demonstrated efficacy based on the analysis of data from vaccinated persons announced on 4/19/2021; Started rolling review process with the European Medicines Agency (EMA) on 3/4/2021; Authorized for "emergency use" in 39 countries as of March 2021; Phase III interim analysis results published on 2/2/2021; "Registered" in Belarus in December 2020; Phase III final control point data analysis results released December 2020, interim data analysis results released November 2020; Phase III (post-registration) trial began September 2020; Phase I/2 began June 2020, results published September 2020; Russian Ministry of Health "registered" vaccine in August 2020, Mass production expected to begin September 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04436471, NCT04437875, NCT04530396, NCT04564716, NCT04587219, NCT04640233, NCT04642339, NCT04656613, NCT04713488, NCT04741061
CanSino Biologics/ Beijing Institute of Biotechnology/ Petrovax
Non-replicating viral vector; Adenovirus Type 5 vector (Ad5-nCoV), (Convidecia™)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for EBOV
Anticipated Next Steps
Anticipated Next Steps
n/a
Authorized for "emergency use" in Argentina, Chile, Hungary, Pakistan, and Mexico, and for "conditional approval" in China as of June 2021; Filed "conditional marketing authorization" with China's National Medical Products Administration (NMPA) on 2/24/2021; Phase III dosed September 2020; Phase II began April 2020, initial results released May 2020, mid-phase results released July 2020; China’s Central Military Commission "approved the use of the vaccine by the military" in June 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ChiCTR2000030906, ChiCTR2000031781, NCT04313127, NCT04341389, NCT04398147, NCT04526990, NCT04540419, NCT04552366, NCT04566770, NCT04568811
AstraZeneca
Non-replicating viral vector; (AZD2816)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase II/III dosed end of June 2021, in both previously vaccinated (with two doses of Vaxzevria or an mRNA vaccine) and unvaccinated adults to determine the safety and immunogenicity of AZD2816, a vaccine for the prevention of COVID-19 caused by variant strains of the SARS-CoV-2 virus
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04973449
ReiThera/ Leukocare/ Univercells/ National Institute of Infectious diseases Lazzaro Spallanzani
Non-replicating viral vector; replication defective simian adenovirus encoding SARS-CoV-2 S (GRAd-CoV2)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase II preliminary data announced July 2021; Phase II/III (COVITAR) study began March 2021; Phase I advanced to second set of three cohorts (aged 65-85 years) in November 2020; Phase I began August 2020, completed the first set of three cohorts (aged 18-55 years), preliminary results announced November 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
EudraCT 2020-002835-31, EudraCT 2020-005915-39, NCT04528641, NCT04791423
Vaxart/ Emergent BioSolutions
Non-replicating viral vector; Oral Vaccine platform
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for InfA, CHIKV, LASV, NORV, EBOV, RVF, HBV, VEE
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase II dosed October 2021; Phase I preliminary data announced 2/3/2021; Phase I dosed October 2020; FDA clearance for Phase I trial received September 2020, recruiment expected to begin September 2020; Pre-clinical results released September 2020; Data from ongoing animal challenge study released October and November 2020. Phase 2 trials in India begin Feb 2022.
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04563702, NCT05067933
BIOCAD
Recombinant Viral Vector AAV5 (Adeno-Associated Virus Type 5)-RBD (Receptor Binding Domain)-S Vaccine, (BCD-250)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II began August 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT05037188
ImmunityBio/ NantKwest
Non-replicating viral vector; [E1-, E2b-, E3-] hAd5-COVID19-Spike/Nucleocapsid; (subcutaneous, oral, and sublingual delivery)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for flu, Chik, Zika, EBOV, LASV, HIV/SIV, cancer
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II/III trial expected to begin Q3 2021 and will study the efficacy, safety, and immunogenicity of ImmunityBio’s T-Cell COVID-19 vaccine as a boost in participants who have already received a spike-only antibody-based vaccine; Expanded trials to test vaccine candidate as a ‘universal boost’ in vaccinated subjects and received approval to test intranasal spray in South Africa as of May 2021; Phase I/II supplemental vaccine boost trial began April 2021; Phase Ib preliminary findings reported on 4/8/2021; Phase I interim safety data announced on 3/15/2021; Phase I dosed in South Africa and the U.S. in March 2021; FDA authorized the expansion of the active Phase I trial and a second trial to test a novel combination of T-cell-based hAd5 subcutaneous prime vaccine with a room-temperature oral or sublingual boost; Phase I interim data announced November 2020; Pre-clinical data released December, November, and July 2020; Phase I trial dosed in the U.S. in October 2020; Selected for US Operation Warp Speed in May 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04591717, NCT04710303, NCT04732468, NCT04843722, NCT04845191
Shenzhen Geno-Immune Medical Institute
LV-SMENP-DC vaccine and antigen-specific CTLs
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II reportedly began March 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04276896
Bharat Biotech International Limited
BBV154; adenovirus vectored, intranasal vaccine
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I began March 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04751682
CyanVac LLC
Intranasal PIV5-vectored vaccine expressing SARS-CoV-2 spike protein; (CVXGA1-001)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I began August 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04973449
City of Hope Medical Center
MVA-based SARS-CoV-2 vaccine; (COH04S1)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase II expected to begin August 2021; Phase I dosed December 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04639466, NCT04977024
Gritstone Oncology, Inc.
Chimpanzee Adenovirus serotype 68 (chAd) and Self-Amplifying mRNA (SAM) vectors expressing either spike alone, or spike plus additional SARS-CoV-2 T cell epitopes (TCE)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I dosed March 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04776317
German Center for Infection Research (DZIF)/ IDT Biologika GmbH/ Universitätsklinikum Hamburg-Eppendorf/ Philipps University Marburg Medical Center/ Ludwig-Maximilians University of Munich
Non-replicating viral vector; MVA-S encoded
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for many pathogens
Anticipated Next Steps
Anticipated Next Steps
n/a
Spike protein of the vector vaccine has now been modified and clinical testing will resume as of 7/16/2021; Phase I/II expected to begin July 2021; Clinical testing suspended January 2021, Phase II postponed until further notice; Phase I dosed October 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04569383, NCT04895449
Altimmune / University of Alabama at Birmingham/ Summit Biosciences
AdCOVID; single-dose, intranasal vaccine; non replicating viral vector; adenovirus-based NasoVAX expressing spike protein
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for influenza
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I data expected to be released June 2021; Additional pre-clinical data released March and May 2021; Phase I commenced enrollment on 2/25/2021; FDA issued clinical hold for planned Phase I trial on 12/22/2020; Pre-clinical data released October 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04679909
McMaster University/ Canadian Institutes of Health Research (CIHR)
Ad5-triCoV/Mac or ChAd-triCoV/Mac, new experimental adenovirus-based vaccines expressing SARS-CoV-2 spike, nucleocapsid and RNA polymerase proteins
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I expected to begin November 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT05094609
Tetherex Pharmaceuticals Corporation
Adneviral vector vaccine, (SC-Ad6-1)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I expected to begin June 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04839042
Institut Pasteur/ TheraVectys
Intranasal lentiviral vector vaccine
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Pre-clinical results published December 2020; Animal study results released July 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Valo Therapeutics Ltd/ ImmunoScape
Adenovirus-based + HLA-matched peptides (Pan-Corona)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
iosBIO (formerly Stabilitech Biopharma Ltd)
Oral Ad5 S; (OraPro-Covid-19)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
University of Helsinki/ University of Eastern Finland/ Rokote Laboratories Finland Ltd
Ad 5 vector for intranasal administration
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Bharat Biotech/ Thomas Jefferson University
Recombinant deactivated rabies virus containing S1; (CoraVax)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Pre-clinical data published October 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Massachusetts Eye and Ear/ AveXis, a Novartis Company/ Viralgen/ Aldevron/ Catalent/ Penn Medicine
AAVCOVID, Adeno-associated viral vector (AAV), spike protein
Product Description
Funder
Funder
n/a
Gates Foundation
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Pre-clinical results released January 2021; Phase I to begin second half of 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
GeoVax / BravoVax/ NIAID/ NIH/ University of Texas Medical Branch
Non-replicating viral vector; MVA encoded VLP
Product Description
Funder
Funder
n/a
National Institute of Allergy and Infectious Diseases (NIAID)/National Institutes of Health (NIH)
Related use
Related use
n/a
Same platform as vaccine candidates for LASV, EBOV, MARV, HIV
Anticipated Next Steps
Anticipated Next Steps
n/a
Awarded a Small Business Innovative Research (SBIR) grant in January 2021 to support the ongoing design, construction, and preclinical testing in preparation for human clinical trials
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
CanSino Biologics/ Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China
Ad5-nCoV
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I recruitment began end of September 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04552366
Globe Biotech Limited, Bangladesh
Adenovirus Type 5 Vector
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
National Center for Genetic Engineering and Biotechnology (BIOTEC)/ GPO, Thailand
Inactivated Flu-based SARS-CoV2 vaccine + Adjuvant
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Ankara University
Adenovirus-based
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
IDIBAPS- Hospital Clinic, Spain
MVA-S
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Greffex
Non-replicating viral vector; Ad5 S (GREVAX™ platform)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for MERS
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Centro Nacional Biotecnologia (CNB-CSIC), Spain
Non-replicating viral vector, MVA expressing structural proteins
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for HIV, HCV, CHIKV, EBOV, Zika, Malaria, Leishmania
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ID Pharma
Sendai virus vector
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
National Research Centre, Egypt
Influenza A H1N1 vector
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
University of Georgia/ University of Iowa
Non-replicating viral vector; parainfluenza virus 5 (PIV5)-based vaccine expressing the spike protein
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for MERS
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Erciyes University
Adeno5-based
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Developer / Researcher
Product Description
PRE
I
II
III
RR
AU
Virus-like particle
Virus-like particle (VLP) vaccines closely resemble viruses but are non-infectious because they contain no viral genetic material. Since VLPs cannot replicate, they provide a safer alternative to attenuated viruses. Examples include the HPV vaccine.
VBI Vaccines / National Research Council of Canada/ Therapure Biomanufacturing
Enveloped virus-like particle (eVLP): Pan-coronavirus vaccine candidate, targeting COVID-19, SARS, and MERS, spike protein (VBI-2900)
Product Description
Funder
Funder
n/a
Coalition for Epidemic Preparedness (CEPI)
Related use
Related use
n/a
Same platform as vaccine candidates for glioblastoma, cytomegalovirus, and Zika
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II trial of VBI-2902a expected to begin March 2021; Phase I trial of VBI-2905, targeting the B.1.351 variant, expected to begin mid-year 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04773665
Arizona State University
Plasmid driven production of virus like particles (VLPs) containing S, M, N and E proteins of SARS-CoV-2
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Arizona State University
Myxoma virus co-expressing S, M, N and E proteins
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Max-Planck Institute for Dynamics of Complex Technical Systems
VLP
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Tampere University
VLPs produced in BEVS
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
University of Manitoba
Virus-like particle-based dendritic cell-targeting vaccine
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ARTES Biotechnology
VLP; eVLP
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for malaria
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
University of Sao Paulo
VLPs peptides/whole virus
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Imophoron Ltd / Bristol University's Max Planck Centre
VLP; ADDomerTM multiepitope display
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Doherty Institute
VLP; unknown
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Mahidol University/ The Government Pharmaceutical Organization (GPO)/ Siriraj Hospital
VLP + Adjuvant
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Medicago Inc./ Dynavax
VLP (CoVLP)+ Adjuvant (CpG 1018)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I to start mid-July 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
IrsiCaixa AIDS Research/ IRTA-CReSA/ Barcelona Supercomputing Centre/ Grifols
S protein integrated in HIV VLPs
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Saiba GmbH
VLP; virus-like particle, based on RBD displayed on virus-like particle
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Medicago Inc./ GSK
VLP (CoVLP)+ Adjuvant
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
OSIVAX
VLP (COVID-19 and SARS1)
Product Description
Funder
Funder
n/a
European Innovation Council (EIC)
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Bezmialem Vakif University
VLP
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Navarrabiomed, Oncoimmunology group
Virus-like particles, lentivirus, and baculovirus vehicles
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Radboud University
ABNCoV2 capsid virus-like particle, formulated with and without the adjuvant MF59
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I of I/II study began March 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04839146, NCT05329220
Scientific and Technological Research Council of Turkey (TÜBITAK)/ Middle East Technical University/ Bilkent University
VLP
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase II expected to begin early June 2021; Phase I dosed end of March 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04818281
Icosavax
VLP displaying the SARS-CoV-2 receptor-binding domain (RBD); (IVX-411)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II began June 2021; Pre-clinical results published October 2020, Topline results published March 2022.
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Serum Institute of India/ Accelagen Pty/ SpyBiotech
RBD SARS-CoV-2 HBsAg VLP vaccine
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I of follow up Phase I/II clinical trial adjuvanted with CpG 1018 dosed December 2020; Phase I/II began September 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ACTRN12620000817943, ACTRN12620001308987
Medicago Inc./ GlaxoSmithKline
VLP; plant-derived VLP adjuvanted with GSK or Dynavax adjuvants; (CoVLP)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for flu, rotavirus, norovirus, West Nile virus, and cancer
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase II interim results released May 2021; Health Canada initiated review of the Interim Order (IO) rolling submission on 4/19/2021; Phase III portion of the ongoing Phase II/III trial began March 2021;Phase II portion of the Phase II/III trial dosed December 2020; Phase II/III began recruiting November 2020; Phase I interim results released November 2020; Phase I began July 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04450004, NCT04636697, NCT04662697
Developer / Researcher
Product Description
PRE
I
II
III
RR
AU
Other Vaccines
From a gene-encoded antibody vaccine to a self-assembling vaccine and more, these are the vaccines being developed that do not fall easily into one of the other product categories or details about its category are not publicly available.
United Biomedical (UBI)/ c19
Unknown
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Clinical testing expected to begin early September 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Oragenics (Noachis Terra)/ Aragen Bioscience
TerraCoV2
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I expected to start in early 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NidoVax
unknown; IMT504 technology
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Vault Pharma/ University of California Los Angeles
nanoparticles (vaults) as second-line defense of infection
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Tulane University
Unknown
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Catholic University/ Millennium Institute of Immunology and Immunotherapy/ Technological Consortium in Clinical Molecular Biomedicine, Chile
Unknown
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
HaloVax (Voltron Therapeutics) / The Vaccine & Immunotherapy Center at the Massachusetts General Hospital
Self-assembling vaccine (fusion protein of a heat shock protein and Avidin, with biotinylated immunogenic peptides)
Product Description
Funder
Funder
n/a
Analog Devices Foundation
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Animal study results by October 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Vivaldi Biosciences/ Esco Aster Pte Ltd
Chimeric vaccine (coronavirus and influenza)
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Adeleke University
Unknown
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
AbVision
AVI-205
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Codiak BioSciences/ Ragon Institute
exoVACC exome platform
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Precision Vaccines Program at Boston Children's Hospital
Unknown
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Vir Biotechnology / GSK
Unknown
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ISR Immune System Regulation
ISR-50
Product Description
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Animal study results expected in Q2 2020, Phase I begins Q4 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Developer / Researcher
Product Description
PRE
I
II
III
RR
AU
The race to produce a COVID-19 vaccine is multifaceted—involving new research on many levels, enormous amounts of fundraising, and unprecedented international cooperation. Check back often with our COVID-19 Vaccine Tracker.

See both the vaccine and treatment approaches being developed at our combined COVID-19 Treatment and Vaccine Tracker.

‍
© 2020 Milken Institute and First Person
Credit

Data sourced from FasterCures, a center of 
the Milken Institute.
Interactive visualization by FirstPerson, a design & storytelling company.
Connect

Covid-19 vaccine tracker

Mobile and tablet experiences coming soon
View treatment and vaccine tracker data here.